Anticoagulation versus placebo for heart failure in sinus rhythm

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Lip, Gregory Y H ^a   Shantsila, Eduard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DICOUMAROL; ENALAPRIL; ETHYL BISCOUMACETATE; HEPARIN; PLACEBO; WARFARIN;

ALL CAUSE MORTALITY; ANTICOAGULANT THERAPY; ARTERY EMBOLISM; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONGESTIVE CARDIOMYOPATHY; HEART FAILURE; HEART INFARCTION; HUMAN; LONG TERM CARE; LUNG EMBOLISM; ODDS RATIO; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINUS RHYTHM; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME; CHRONIC DISEASE; HEART RATE; META ANALYSIS; MORTALITY; ORAL DRUG ADMINISTRATION; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; CARDIOMYOPATHY, DILATED; CHRONIC DISEASE; HEART FAILURE; HEART RATE; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; WARFARIN;

EID: 84907401008     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003336.pub3     Document Type: Review

References (28)

1. Anderson GM, Hull E. The effects of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. American Heart Journal 1950;39:697-702.
2. Griffith GC, Stragnell R, Levinson DC, Moore FJ, Ware AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Annals of Internal Medicine 1952;37:867-87.
3. Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. New England Journal of Medicine 1950;242:208-11.
4. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study. The European Journal of Heart Failure 2006;8:428-432.
5. Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, et al.The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal 2004;148:157-64.
6. Swedberg K, for the CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine 1987;316:1429-35.
7. Echemann M, Alla F, Briancon S, Juilliere Y, Virion JM, Mertes PM, et al.Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study) [Epidemiologie de l'insuffisance cardiaque avancee en Lorraine]. European Journal of Heart Failure 2002;4(5):647-54..
8. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Bradenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. American Journal of Cardiology 1981;47:525-31.
9. Kyrle PA, Korninger C, Gossinger H, Glogar D, Lechner K, Niessner H, et al.Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thrombosis and Haemostasis 1985;54:521-3.
10. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW. Low risk of arterial embolization in outpatients awaiting cardiac transplantation [abstract]. Circulation 1993;88 Suppl I:603.
11. Falk R, Pollack A, Tandon PK, Packer M. The effect of warfarin on prevalence of stroke in severe heart failure. Journal of the American College of Cardiology 1993;21 Suppl A:218A.
12. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, et al.Ventricular dysfunction and the risk of stroke after myocardial infarction. New England Journal of Medicine 1997;336:251-7.
13. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology 1998;31:749-53.
14. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN, for the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87 Suppl VI:94-101.
15. Visser LE, Bleumink GS, Trienekens PH, Vulto AG, Hofman A, Stricker BH. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. British Journal of Haematology. 2004;127(1):85-9.
16. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al.WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. New England Journal of Medicine 2012;366:1859-69.
17. Messie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, et al.Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation Mar 31;119(12):1616-24.
18. Wishart JH, Chapman CB. Dicumarol therapy in congestive heart failure. New England Journal of Medicine 1948;239:701-4.
19. The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. New England Journal of Medicine 1990;323:1505-11.
20. Brown A, Cleland JGF. Influence of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. European Heart Journal 1998;19:1063-9.
21. Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. Archives of Internal Medicine 1977;137:197-202.
22. Edep ME, Shah NB, Massie BM. Differences between primary care physicians and cardiologists in the management of congestive heart failure: relationship to practice guidelines. Journal of the American College of Cardiology 1997;30:518-26.
23. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Reviewers' Handbook 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
24. Husted S, Andraesen F. Problems encountered in long-term treatment with anticoagulants. Acta Medica Scandinavica 1976;200:379-84.
25. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin. Incidence and prediction by factors known at the start of outpatient therapy. American Journal of Medicine 1989;87:144-52.
26. Lebvre C, Manheimer E, Glanville J. Chapter 6: Searching for Studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
27. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989;I:175-9.
28. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke Prevention in Atrial Fibrillation Investigators. Circulation 1991;84:527-39.